Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alvotech

8.10
-0.2700-3.23%
Volume:36.81K
Turnover:298.34K
Market Cap:2.16B
PE:-9.36
High:8.38
Open:8.38
Low:8.00
Close:8.37
Loading ...

BUZZ-Alvotech rallies after US biosimilar launch

Reuters
·
22 Feb

Alvotech Sa Shares Rise 5.6% After Co and Teva Pharma Launch Biosimilar to J&J's Stelara in US

THOMSON REUTERS
·
22 Feb

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday Amid Ongoing Tariff Uncertainties

MT Newswires Live
·
21 Feb

Teva Pharmaceutical US Affiliate, Alvotech Selarsdi Injection Now Available in US

MT Newswires Live
·
21 Feb

Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US

Reuters
·
21 Feb

Teva Pharma and Alvotech launch Stelara biosimilar in US

Reuters
·
21 Feb

BRIEF-Teva And Alvotech Announce Selarsdi™ Injection Now Available In The U.S.

Reuters
·
21 Feb

Teva and Alvotech Announce Selarsdi™ (Ustekinumab-Aekn) Injection NOW Available in the U.S.

THOMSON REUTERS
·
21 Feb

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

GlobeNewswire
·
21 Feb

Alvotech, Teva Pharmaceutical's Bionsimlar Eye Disorder Potential Treatment Accepted for FDA Review

MT Newswires Live
·
18 Feb

BUZZ-Teva rises as FDA accepts to review biosimilar to eye disease drug Eylea

Reuters
·
18 Feb

Alvotech’s AVT06 Biosimilar Application Accepted by FDA

TIPRANKS
·
18 Feb

Alvotech and Teva’s BLA filing for AVT06 accepted by FDA

TIPRANKS
·
18 Feb

BRIEF-Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application

Reuters
·
18 Feb

Teva: Process to Obtain Regulatory Approval Is Anticipated to Be Completed in Q4 of 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - FDA Accepts for Review Bla for Alvotech's Biosimilar to Eylea

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval for Avt06 Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for Avt06, a Proposed Biosimilar to Eylea® (Aflibercept)

THOMSON REUTERS
·
18 Feb

Alvotech Initiated at Buy by UBS

Dow Jones
·
15 Feb